National Institute for Biological Standards and Control
WHO – UNAIDSHIV Vaccine Initiative*
Materials Transfer Agreement: for-Profit Institutions
*The WHO-UNAIDS HIV Vaccine initiative is a joint activity of the World Health Organisation (WHO) and the United Nations Programme on HIV/AIDS (UNAIDS)
Reagent(s) Requested: (please continue on separate sheet if necessary):
1.Catalogue Number: CFAR ...... Description
2.Catalogue Number: CFAR ...... Description
3.Catalogue Number: CFAR ...... Description
4.Catalogue Number: CFAR ...... Description
Justification for request (please continue on separate sheet if necessary):
Reagents are provided on the following conditions:
1.The entity requesting and receiving the Materials, hereinafter referred to as “The Receiving Party”, agrees that the material is for research use only and not intended for use in humans. Any use contrary to this statement, as well as use in humans of materials incorporating the Material, are at the sole responsibility of the Receiving Party.
2.The Receiving Party will not permit the Material or any part thereof to come into the possession or control of any other entity or person, except those engaged in research under the supervision of the Receiving Party who have accepted the same obligations in respect of the Material as set forth in this document.
FOR OFFICE USE ONLY
Approved (WHO): YES / NO / Approved (NIBSC): YES / NO / Date Sent:Name: / Initials: / Sent by:
- This agreement is a material transfer agreement. The supply of the material hereunder does not in any way constitute a license to make, use or sell the Material. The Material is provided to the Receiving Party for the research use described above only. The Receiving Party agrees that the Material itself may not be used for commercial purposes, unless prior written authorisation has been granted by WHO - UNAIDS. Such authorisation is not, however, required for using the Material for the commercial purpose of making novel non-infectious derivatives, which incorporate the Material. Nothing contained herein will furthermore be construed as restricting the use of such novel non-infectious derivatives for commercial purposes, including, but not limited to, the commercial production of pharmaceutical products. However, in the event the Material provided hereunder contributes to the development of a product, which is capable of exploitation on an industrial or commercial scale, the Receiving Party shall, account being taken of the relative importance of the contribution of WHO-UNAIDS to the development of such product, use reasonable efforts to ensure that (a) this product is actually developed and made widely available; (b) insofar, as circumstances permit, this product is available, on beneficial terms, to the public health authorities in WHO – UNAIDS Member States, particularly in developing countries.
- The Material may not be transferred or sold to any third party, without the prior authorisation in writing from WHO – UNAIDS.
5.Any publication or presentation of (the results of) the research using the Material, will duly acknowledge WHO–UNAIDS, the Programme EVA Centre for AIDS Reagents and the institutes involved in the provision of the Material or the Repository including those institutes that were involved in the collection of the relevant blood samples and the relevant virus and strain isolation. The receiving Party agrees to consult with WHO- AIDS in that respect before such publication is published or presentation is made.
- Any infectious or potentially infectious materials will only be handled in appropriate containment facilities by fully trained and competent staff. (See WHO Biosafety Guidelines; WHO/AIDS Series No 9, Geneva, 1991; HIV-the causative agent of AIDS and related conditions: Second revision of guidelines.) The Receiving Party will comply with all applicable national legislation when using the Material, including, but not limited to, applicable health safety regulations. WHO – UNAIDS and the Repository accept no liability whatsoever for any damage, injury or death resulting from the use of the Material.
- The Receiving Party agrees to assume all responsibility for any claims, cost, damages or expenses resulting from or otherwise related to the possession and use of the Material and materials incorporating the Material.
- On completion of the research using the Material, the Receiving Party will continue to abide by the terms and conditions set forth in this document.
- The foregoing terms and conditions reflect the terms and conditions pursuant to which WHO – UNAIDS agrees to make the above-mentioned Strains/Reagents available. WHO – UNAIDS expressly reserves the right to make the use of the other strains/reagents subject to different terms and conditions than those contained herein.
If the foregoing conditions are acceptable to you, complete this form and send it to the addresses below. Applications by fax must be followed by original signed agreement via the post. Please note, however that signature of this document does not automatically imply that you will receive the Materials. Once your request has been approved, arrangements will be made for dispatch of the Material to you (of which arrangements you will be notified). You may wish to take a photocopy of this form for your records. The submitted form must contain original, ink signatures: photocopied or stamped signatures are NOT acceptable.
I certify that I have read and accepted the conditions listed above and I warrant that I have the full authority to
execute this agreement and to hereby bind the Institute/other entity receiving the Material (i.e. the receiving party):
Applicant Signature:...... Date:......
Print Name:...... Institute:.....
Position: ......
This application has my full support and approval:
Counter Signature by Officer of the Institution or Company:......
Print Name:...... Date:......
Position in Institution or Company: ......
Full address to which materials should be sent (PLEASE USE BLOCK CAPITALS):
Telephone Number: ...
Fax Number: ......
Email: ......
Purchase Order number or copy of Purchase Order:......
If known, VAT exemption number or certificate. (VAT* is relevant to EU customers only):......
*UK equivalent to the TVA, BTW, MVD, MWS, OTIA and IVA charged in other EU Member States.
Instructions for ordering reagents from the Centre for AIDS Reagents:
- Scientists requesting additional reagents which are not WHO-UNAIDS reagents must also complete the current version of the Centre for AIDS Reagents “Reagent Release Agreement”. This can be emailed to you on request or found on our website at:
- Completed forms can be submitted by FAX, but the original signed copies must also be sent via post.
- Failure to complete all relevant sections of this form may result in the delay of reagents being dispatched.
- Completed forms must contain
- Scientific justification for request.
- Signature of countersignatory (principle investigator or Head of Department).
- Telephone number, fax number and email address.
- Copy of Purchase Order or Purchase Order number.
- If known, VAT exemption number or certificate. (VAT* is relevant to EU customers only)
- We aim to dispatch all orders within 10 working days of receipt of the complete order, including all relevant paperwork and permits, provided reagents are available for dispatch.
- Import Permit
Where necessary, a valid importation permit must be included. Contact your local customs authority if you are unsure about import regulations. The sites below may be of some help for importation restrictions and requirements:
The IATA Dangerous Goods Regulations:
Etiological Agent Import Permit Program (USA):
- Disclaimer
Although materials provided through the repository are presented on good faith, Programme EVAThe Centre for AIDS Reagents CFAR (EVA CFAR) at the National Institute of Biological Standards and Control, a Centre of the Health Protection Agency (NIBSC-HPA) makes no representations or warranties as to the safety, accuracy, usefulness or completeness of information and products disclosed. Materials provided to repository users are for research purposes only and customers must validate these products for their own research use.
Please return the completed form to:
Dr Uli Fruth
Initiative for Vaccine Research
World Health Organization
Avenue Appia 20
1203 Geneva
Switzerland
phone: (+41-22) 791.26.78
fax: (+41-22) 791.48.60
e-mail:
Dr S Osmanov MD, PhD
WHO-UNAIDS HIV Vaccine Initiative (HVI)
Initiative for Vaccine Research (IVR)
Health Technology and Pharmaceuticals (HTP)
World Health Organisation (WHO)
20 Avenue Appia
1211 Geneva 27
Switzerland
Tel: (41-22) 791 4393, Fax: (41-22) 791 4865
Website:
and also send a copy to:CFAR, Division of Retrovirology
National Institute for Biological Standards and Control
Blanche Lane, South Mimms, Potters Bar, HertsEN6 3QG, UK
Tel: +44 1707 641000 Fax: +44 1707 641060 / 641050
Email enquiries to:
UserRef: RET/CFARFORM7Version: 4.00Issue Status: ISSUED
Document Serial No: 4962 from Database: NIBSC
Controlled by WorkBench ProfessionalPage 1 of 5Issue Date: 30/06/2011